It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Tourette Syndrome Drug Treatment Study

Clinical Trial Title: 
A phase 2a, open-label trial evaluating the efficacy, safety, and pharmacokinetics of a new drug in adult subjects with Tourette Syndrome
Clinical Trial Protocol ID: 
14052707
Clinical Trial Investigator Name: 
Katie Kompoliti, MD
Clinical Trial Protocol Description: 

This study involves the use of a new drug. The main purpose of this study is to evaluate how SNC-102 works in the treatment of Tourette Syndrome. It will also look at how safe and tolerable it is. It is anticipated that a total of 16 subjects will participate. If you agree to participate you may be one of up to 8 subjects expected to participate in this study at Rush University Medical Center. Study participation will last up to 11 weeks, and will include about 7 study visits at the medical center.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be 18-75 years of age.
  • Have a diagnosis of Tourette Syndrome according to DSM-V criteria for Tourette’s Disorder, as follows:
    • Have both multiple motor and one or more vocal tics present at some time during the illness, although not necessarily concurrently.
    • Have tics that may wax and wane in frequency but have persisted for more than 1 year since first tic onset.
    • Have onset before age 18 years.
  • Have oderate to severe tics as indicated by a CGI severity score of 4 or higher.
  • If using a permitted medication (SSRI, SNRI, alpha-2 agonist, benzodiazepine, dopamine antagonist or stimulant), the dose has been stable for at least 28 days prior to the Screening Visit and is expected to remain stable through the conclusion of the study.

You will be excluded from the study if any of the following criteria apply to you:

  • Have an initiation or a change in dosage of any other drug for treating Tourette Syndrome within 28 days prior to the Screening Visit, or anticipation that any other drug for treating Tourette Syndrome will be initiated or changed during the period of the study.
  • Have a diagnosis of epilepsy.
  • Have had treatment with any exclusionary drugs.
  • Have an unstable psychiatric status.
  • Have an active drug or alcohol dependence or abuse.

This is a partial list of inclusion and exclusion criteria. 

Clinical Trial Area: 
Developmental Disorders
Mental Health Disorders
Pediatric Neurological Disorders
Contact Phone: 
312-563-2900 (Press 4/Code TS Study)
Contact Name: 
Katie Kompoliti, MD